Forecast of Global Hyperimmune Globulins Consumption 麻豆原创 2023

Publication ID:

PB29180057

Publication Date:

September 3, 2018

Pages:

166

Publisher:

MRRPB2

Countries:

Global [1]

USD 4,660.00

Pharma & Healthcare [2]

Healthcare [3]

Description:

Hyperimmune Globulins market will register a 9.7% CAGR in terms of revenue, reach US$ 1960 million by 2023, from US$ 1120 million in 2017.

听

Forecast of Global Hyperimmune Globulins Consumption 麻豆原创 2023

听

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

In the last several years, global market of Hyperimmune Globulins developed rapidly, with an average growth rate of 6%. In 2017, global revenue of Hyperimmune Globulins is nearly 1150 million USD; the actual production is about 40 million units.

The classification includes the Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and others, and the proportion of Rabies Immunoglobulins in 2017 is about 44.2%, with the largest market share.

Hyperimmune Globulins is widely used in Government Institutions, Private Sector and Other. The most proportion of Hyperimmune Globulins is sold in Government Institutions, and the proportion in 2017 is about 62.7%.听

Over the next five years, study projects that Hyperimmune Globulins will register a 9.7% CAGR in terms of revenue, reach US$ 1960 million by 2023, from US$ 1120 million in 2017.

听

This report presents a comprehensive overview, market shares, and growth opportunities of Hyperimmune Globulins market by product type, application, key manufacturers and key regions.

听

To calculate the market size, study considers value and volume generated from the sales of the following segments:

听

Segmentation by product type:
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Others
Segmentation by application:
Government Institutions
Private Sector
Other

听

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

听

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
CSL Behring
Grifols听
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

听

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

听

Research objectives
To study and analyze the global Hyperimmune Globulins consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Hyperimmune Globulins market by identifying its various subsegments.
Focuses on the key global Hyperimmune Globulins manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hyperimmune Globulins with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hyperimmune Globulins submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hrs) post payment.

Table Of Contents:

Table of Contents

2018-2023 Global Hyperimmune Globulins Consumption 麻豆原创 Report

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 麻豆原创 Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Hyperimmune Globulins Consumption 2013-2023
2.1.2 Hyperimmune Globulins Consumption CAGR by Region
2.2 Hyperimmune Globulins Segment by Type
2.2.1 Hepatitis B Immunoglobulins
2.2.2 Rabies Immunoglobulins
2.2.3 Tetanus Immunoglobulins
2.2.4 Others
2.3 Hyperimmune Globulins Consumption by Type
2.3.1 Global Hyperimmune Globulins Consumption 麻豆原创 Share by Type (2013-2018)
2.3.2 Global Hyperimmune Globulins Revenue and 麻豆原创 Share by Type (2013-2018)
2.3.3 Global Hyperimmune Globulins Sale Price by Type (2013-2018)
2.4 Hyperimmune Globulins Segment by Application
2.4.1 Government Institutions
2.4.2 Private Sector
2.4.3 Other
2.5 Hyperimmune Globulins Consumption by Application
2.5.1 Global Hyperimmune Globulins Consumption 麻豆原创 Share by Application (2013-2018)
2.5.2 Global Hyperimmune Globulins Value and 麻豆原创 Share by Application (2013-2018)
2.5.3 Global Hyperimmune Globulins Sale Price by Application (2013-2018)

3 Global Hyperimmune Globulins by Players
3.1 Global Hyperimmune Globulins Sales 麻豆原创 Share by Players
3.1.1 Global Hyperimmune Globulins Sales by Players (2016-2018)
3.1.2 Global Hyperimmune Globulins Sales 麻豆原创 Share by Players (2016-2018)
3.2 Global Hyperimmune Globulins Revenue 麻豆原创 Share by Players
3.2.1 Global Hyperimmune Globulins Revenue by Players (2016-2018)
3.2.2 Global Hyperimmune Globulins Revenue 麻豆原创 Share by Players (2016-2018)
3.3 Global Hyperimmune Globulins Sale Price by Players
3.4 Global Hyperimmune Globulins Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Hyperimmune Globulins Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Hyperimmune Globulins Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Hyperimmune Globulins by Regions
4.1 Hyperimmune Globulins by Regions
4.1.1 Global Hyperimmune Globulins Consumption by Regions
4.1.2 Global Hyperimmune Globulins Value by Regions
4.2 Americas Hyperimmune Globulins Consumption Growth
4.3 APAC Hyperimmune Globulins Consumption Growth
4.4 Europe Hyperimmune Globulins Consumption Growth
4.5 Middle East & Africa Hyperimmune Globulins Consumption Growth

5 Americas
5.1 Americas Hyperimmune Globulins Consumption by Countries
5.1.1 Americas Hyperimmune Globulins Consumption by Countries (2013-2018)
5.1.2 Americas Hyperimmune Globulins Value by Countries (2013-2018)
5.2 Americas Hyperimmune Globulins Consumption by Type
5.3 Americas Hyperimmune Globulins Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Hyperimmune Globulins Consumption by Countries
6.1.1 APAC Hyperimmune Globulins Consumption by Countries (2013-2018)
6.1.2 APAC Hyperimmune Globulins Value by Countries (2013-2018)
6.2 APAC Hyperimmune Globulins Consumption by Type
6.3 APAC Hyperimmune Globulins Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Hyperimmune Globulins by Countries
7.1.1 Europe Hyperimmune Globulins Consumption by Countries (2013-2018)
7.1.2 Europe Hyperimmune Globulins Value by Countries (2013-2018)
7.2 Europe Hyperimmune Globulins Consumption by Type
7.3 Europe Hyperimmune Globulins Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Hyperimmune Globulins by Countries
8.1.1 Middle East & Africa Hyperimmune Globulins Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Hyperimmune Globulins Value by Countries (2013-2018)
8.2 Middle East & Africa Hyperimmune Globulins Consumption by Type
8.3 Middle East & Africa Hyperimmune Globulins Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 麻豆原创 Challenges and Impact
9.3 麻豆原创 Trends

10 麻豆原创ing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct 麻豆原创ing
10.1.2 Indirect 麻豆原创ing
10.2 Hyperimmune Globulins Distributors
10.3 Hyperimmune Globulins Customer

11 Global Hyperimmune Globulins 麻豆原创 Forecast
11.1 Global Hyperimmune Globulins Consumption Forecast (2018-2023)
11.2 Global Hyperimmune Globulins Forecast by Regions
11.2.1 Global Hyperimmune Globulins Forecast by Regions (2018-2023)
11.2.2 Global Hyperimmune Globulins Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States 麻豆原创 Forecast
11.3.2 Canada 麻豆原创 Forecast
11.3.3 Mexico 麻豆原创 Forecast
11.3.4 Brazil 麻豆原创 Forecast
11.4 APAC Forecast by Countries
11.4.1 China 麻豆原创 Forecast
11.4.2 Japan 麻豆原创 Forecast
11.4.3 Korea 麻豆原创 Forecast
11.4.4 Southeast Asia 麻豆原创 Forecast
11.4.5 India 麻豆原创 Forecast
11.4.6 Australia 麻豆原创 Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany 麻豆原创 Forecast
11.5.2 France 麻豆原创 Forecast
11.5.3 UK 麻豆原创 Forecast
11.5.4 Italy 麻豆原创 Forecast
11.5.5 Russia 麻豆原创 Forecast
11.5.6 Spain 麻豆原创 Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt 麻豆原创 Forecast
11.6.2 South Africa 麻豆原创 Forecast
11.6.3 Israel 麻豆原创 Forecast
11.6.4 Turkey 麻豆原创 Forecast
11.6.5 GCC Countries 麻豆原创 Forecast
11.7 Global Hyperimmune Globulins Forecast by Type
11.8 Global Hyperimmune Globulins Forecast by Application

12 Key Players Analysis
12.1 CSL Behring
12.1.1 Company Details
12.1.2 Hyperimmune Globulins Product Offered
12.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 CSL Behring News
12.2 Grifols听
12.2.1 Company Details
12.2.2 Hyperimmune Globulins Product Offered
12.2.3 Grifols听 Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Grifols听 News
12.3 Biotest
12.3.1 Company Details
12.3.2 Hyperimmune Globulins Product Offered
12.3.3 Biotest Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Biotest News
12.4 Kedrion
12.4.1 Company Details
12.4.2 Hyperimmune Globulins Product Offered
12.4.3 Kedrion Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Kedrion News
12.5 CBPO
12.5.1 Company Details
12.5.2 Hyperimmune Globulins Product Offered
12.5.3 CBPO Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 CBPO News
12.6 Emergent (Cangene)
12.6.1 Company Details
12.6.2 Hyperimmune Globulins Product Offered
12.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Emergent (Cangene) News
12.7 Kamada
12.7.1 Company Details
12.7.2 Hyperimmune Globulins Product Offered
12.7.3 Kamada Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Kamada News
12.8 CNBG
12.8.1 Company Details
12.8.2 Hyperimmune Globulins Product Offered
12.8.3 CNBG Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 CNBG News
12.9 Hualan Bio
12.9.1 Company Details
12.9.2 Hyperimmune Globulins Product Offered
12.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Hualan Bio News
12.10 Shanghai RAAS
12.10.1 Company Details
12.10.2 Hyperimmune Globulins Product Offered
12.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Shanghai RAAS News
12.11 Sichuan Yuanda Shuyang
12.12 ADMA Biologics

13 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.